Schedule 13D ownership disclosure

Edge Therapeutics, Inc.

Security class unavailable · CUSIP: 279870109

Event date: 2016-03-11

Legacy cover-page extraction is best effort and may not include every reporting person.

Filing-level shares
2,852,711
Percent of class
9.9000%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0001144204-16-088279
Form type
SC 13D/A
Filer
PDS Biotechnology Corp
CIK
CIK 1472091
Filed
Mar 16, 2016
Reporting period
Mar 11, 2016
Description
Schedule 13D beneficial ownership

Explore SEC Filings Hub